ÂÜÀòÂÒÂ×

Richard Ho is a highly experienced biotechnology executive with a strong background in scientific leadership and research development. Currently serving as the Chief Technology Officer at Amaro Therapeutics, Inc. since January 2021, Richard previously held the role of Chief Scientific Officer at Cotinga Pharmaceuticals and Critical Outcome Technologies, Inc. Notable achievements include leading a diverse team at Marina Biotech, contributing to a Phase 1 study of an oral RNAi therapeutic, and overseeing biosimulation collaborations at Entelos. Richard's career spans various roles in significant companies, including J&J and Rosa & Co., and is supported by an MD-PhD in immunopharmacology from the Jacobs School of Medicine and Biomedical Sciences, along with an A.B. in physics from Harvard University.